Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Lee Royall

Gastroenterology Charleston, SC Medical Doctor

NPI 1578569067 CMS profile 116395

1962 Charlie Hall Blvd, Charleston, SC 29414

Open in the dashboard

General payments

$5,556

285 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lee Royall of Charleston, SC is reported in the CMS Open Payments database as having received $5,556 across 285 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 69th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,743 91
2024 General $1,144 63
2023 General $811 48
2022 General $374 20
2021 General $58 4
2020 General $635 11
2019 General $790 48

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lee Royall
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Lee Royall were reported at $1,743. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Lee Royall Gastroenterology median Middle half National median
2019 $790 $417 $126–$1,100 $163
2020 $635 $224 $74–$624 $114
2021 $58 $352 $106–$1,054 $132
2022 $374 $448 $129–$1,270 $149
2023 $811 $533 $150–$1,390 $160
2024 $1,144 $605 $160–$1,606 $164
2025 $1,743 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,773 114 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $992 30 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $303 16 payments
  4. Janssen Biotech, Inc. $283 20 payments
  5. Ardelyx, Inc. $219 10 payments
  6. Regeneron Healthcare Solutions, Inc. $212 9 payments
  7. Phathom Pharmaceuticals, Inc. $192 11 payments
  8. Madrigal Pharmaceuticals $183 8 payments
  9. Boston Scientific Corporation $168 4 payments
  10. Sandoz Inc. $141 9 payments
  11. Other $1,091 54 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,529 283 payments
  2. Education $14 1 payment
  3. Consulting Fee $13 1 payment
Products named General payments · program years 2019–2025
  1. RINVOQ $791 35 payments
  2. RELISTOR $490 1 payment
  3. XIFAXAN $366 19 payments
  4. SKYRIZI Immunology $361 19 payments
  5. CREON $324 33 payments
  6. SKYRIZI Immunology $300 15 payments
  7. LINZESS $298 33 payments
  8. STELARA $280 15 payments
  9. ENTYVIO $251 12 payments
  10. IBSRELA $219 10 payments
  11. Other $2,670 156 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

1,460

Median for Gastroenterology: 569

Drug cost

$661,752

Median for Gastroenterology: $104,976

Branded share of claims

12.7%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Stelara Ustekinumab Brand 14 $389,607
Humira(Cf) Pen Adalimumab Brand 14 $95,362
Creon Lipase/Protease/Amylase Brand 12 $67,364
Linzess Linaclotide Brand 31 $34,883
Relistor Methylnaltrexone Bromide Brand 11 $26,328
Dexlansoprazole Dr Dexlansoprazole Brand 37 $14,761
Colesevelam Hcl Generic 34 $7,178
Omeprazole Generic 350 $5,862
Pantoprazole Sodium Generic 399 $5,416
Famotidine Generic 176 $4,299

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 40 billing codes

Paid by Medicare

$171,967

Medicare's payments for the services billed

Medicare patients

815

Average age 73

Services billed

1,689

461 women, 354 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 47%
Diabetes 29%
Ischemic heart disease 23%
Depression 22%
Chronic kidney disease 19%
Cancer 19%
Osteoporosis 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
  • AbbVie, Inc. $132
$132 — —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $132
$132 — —
CREON
  • AbbVie, Inc. $87
$87 12 —
IBSRELA
  • Ardelyx, Inc. $84
$84 — —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $70
$70 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

285 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record